LYR-210 is intended for the treatment of chronic rhinosinusitis. Credit: Credit: aslysun via Shutterstock.com.

Lyra Therapeutics has restarted screening and enrolment of patients in its second pivotal Phase III clinical trial, ENLIGHTEN II, of LYR-210 for the treatment of chronic rhinosinusitis (CRS).

A bioresorbable nasal implant, LYR-210 is designed as an alternative to sinus surgery for CRS patients who remain symptomatic although treated.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It delivers an anti-inflammatory therapy, mometasone furoate, to the sinonasal passages continuously for up to six months and treats CRS.

ENLIGHTEN II is a part of Lyra’s ENLIGHTEN programme including ENLIGHTEN I study, whose enrolment is ongoing.

Each ENLIGHTEN trial will enrol 180 CRS patients who have failed medical management and have not had prior ethmoid sinus surgery.

Patients will be randomised in a 2:1 fashion to either receive LYR-210 (7500µg mometasone furoate (MF)) against a control.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lyra president and CEO Maria Palasis said: “Our in-house manufacturing team was able to expedite the increased production of LYR-210 to allow us to resume enrollment in ENLIGHTEN II ahead of our original expectation of third quarter of 2023.

“We believe that Lyra’s internal manufacturing capabilities and quality systems will continue to strengthen our ability to expedite our promising candidates toward approval and commercialization, while reducing regulatory risk and risks associated with technology transfer to third parties.”

ENLIGHTEN II trial’s enrolment is expected to be completed in the second half of 2024, while the pivotal data of ENLIGHTEN I is anticipated in first half of 2024.

The two pivotal trials’ data of LYR-210 will be used to support an anticipated new drug application to the US Food and Drug Administration.